HONG KONG – Cstone Pharmaceuticals Co. Ltd. inked a licensing agreement with Legochem Biosciences Inc. for LCB-71, the latter’s antibody-drug conjugate.
HONG KONG – Cstone Pharmaceuticals Co. Ltd. inked a licensing agreement with Legochem Biosciences Inc. for LCB-71, the latter’s antibody-drug conjugate.
LONDON – Araris Biotech AG has raised CHF12.7 million (US$16.8 million) in a seed funding round to take forward what it claims is the holy grail for antibody-drug conjugates (ADCs), a linker technology that allows for the attachment of any payload to any antibody, without the need for engineering.
Antibody-drug conjugates (ADCs) are making a comeback. After a relatively slow start with Adcetris (brentuximab vedotin, Seattle Genetics Inc.) and Kadcyla (ado-trastuzumab emtansine, Roche Holding AG) approved by the FDA in 2011 and 2013, respectively, the regulatory activity has swelled with four FDA approvals over the last nine months.
In the company’s largest acquisition and potentially the fifth biggest biotech M&A ever, Gilead Sciences Inc. will acquire Immunomedics Inc. for $21 billion in a move that substantially transforms Gilead’s oncology portfolio.
Though falling short of the outright takeover that some may have hoped for, Merck & Co. Inc.’s dual tie-ups with Seattle Genetics Inc. (Seagen) put the latter in solid position to shop for acquisitions of its own.
About two weeks after European regulators gave their go-ahead for Blenrep (belantamab mafodotin-blmf), the B cell maturation antigen (BCMA)-targeting therapy from Glaxosmithkline plc (GSK) for relapsed/refractory multiple myeloma (MM), the FDA did likewise.
LONDON – Astrazeneca plc is broadening its antibody-drug conjugate (ADC) relationship with Daiichi Sankyo Co. Ltd. in a potential $6 billion development and commercialization deal.
LONDON – Astrazeneca plc is broadening its antibody-drug conjugate (ADC) relationship with Daiichi Sankyo Co. Ltd. in a potential $6 billion development and commercialization deal. The two companies are to work together on DS-1062, Daiichi’s trophoblast antigen2 (TROP2) ADC, which is in phase I development in multiple tumors that express the cell surface glycoprotein. These include breast cancer and non-small-cell lung cancer (NSCLC), areas of strategic focus for Astrazeneca. The agreement builds on the March 2019 $6.9 billion pact between the two for Enhertu (trastuzumab deruxtecan), the HER2-targeted ADC now on course for blockbuster status, following FDA approval in December 2019 and U.S. launch at the start of the year.
DUBLIN – Tubulis GmbH raised €10.7 million (US$12.3 million) in a series A round to progress a next-generation antibody-drug conjugate (ADC) platform, which, it claims, will improve both the stability of ADC constructs and the efficiency with which they are generated.
RSS
